{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:59:07Z","timestamp":1790456347085,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2026.08.036","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:58:35Z","timestamp":1787727515000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival"],"prefix":"10.1016","author":[{"given":"Ruth C.","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Remde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Roscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon Lopez","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bene\u0161ov\u00e1-Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.08.036_bib0001","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0002","unstructured":"U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. Accessed September 9, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0003","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2967\/jnumed.125.270940","article-title":"\u03b1-Therapy and combination strategies to overcome resistance and enhance clinical outcomes in prostate cancer","volume":"66","author":"Karmann","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.119.234559","article-title":"Patients resistant against PSMA-targeting \u03b1-radiation therapy often harbor mutations in DNA damage-repair-associated genes","volume":"61","author":"Kratochwil","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104131","article-title":"Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer","volume":"10","author":"Rami","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103923","article-title":"The power of precision: Unravelling the radiobiology of targeted radionuclide therapy","volume":"48","author":"Khanna","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0007","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.7150\/thno.107963","article-title":"Targeted radioligand therapy: Physics and biology, internal dosimetry and other practical aspects during 177Lu\/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer","volume":"15","author":"Dadgar","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0008","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for targeted therapy: Physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0009","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/ijms27052290","article-title":"Alpha and beta emitters in translational nuclear medicine: Clinical advances, challenges, and future direction","volume":"27","author":"Karimi","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00259-025-07427-4","article-title":"Biodistribution of free francium-221 and bismuth-213 in tumour-bearing SCID mice after successful development of actinium-225\/francium-221 radionuclide generator set-up","volume":"53","author":"Zitzmann-Kolbe","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0011","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0012","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2023.110819","article-title":"Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals","volume":"197","author":"Bauder-W\u00fcst","year":"2023","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0014","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088239","article-title":"DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy","volume":"9","author":"Graf","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109032","article-title":"Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancer","volume":"146-147","author":"Savio","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0017","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.3390\/ijms21186602","article-title":"Comparison of high- and low-LET radiation-induced DNA double-strand break processing in living cells","volume":"21","author":"Roobol","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109044","article-title":"Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy","volume":"146-147","author":"Cruz-Nova","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0020","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1021\/acs.jmedchem.1c00762","article-title":"BAY-8400: A novel potent and selective DNA-PK inhibitor which shows synergistic efficacy in combination with targeted alpha therapies","volume":"64","author":"Berger","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0021","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.7150\/thno.82963","article-title":"DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo","volume":"13","author":"Reuvers","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2026.08.036_bib0022","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ijrobp.2015.12.268","article-title":"M3814, a DNA-dependent protein kinase inhibitor (DNA-PKi), potentiates the effect of ionizing radiation (IR) in xenotransplanted tumors in nude mice","volume":"94","author":"Damstrup","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:09:35Z","timestamp":1790453375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626042276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"alternative-id":["S0360301626042276"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.036","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}